Evidence map›Paper›PMID 42124595›Full record

ArticlebioRxiv : the preprint server for biology2026

A 5-hydroxymethylcytosine DNA glycosylase provides defense against T-even bacteriophages.

Adriana Mejía-Pitta, Zhiying Zhang, Amer A Hossain, Karolina Bartosik, Christian F Baca, Christopher Peralta, Henrik Molina, Marianna Teplova, Sean F Brady, Ronald Micura and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adriana Mejía-PittaLaboratory of Bacteriology, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.
Zhiying ZhangStructural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Amer A HossainLaboratory of Bacteriology, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.
Karolina BartosikDepartment of Organic Chemistry, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.
Christian F BacaLaboratory of Bacteriology, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.
Christopher PeraltaProteomics Resource Center, The Rockefeller University, New York, NY, USA.
Henrik MolinaProteomics Resource Center, The Rockefeller University, New York, NY, USA.
Marianna TeplovaStructural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Sean F BradyLaboratory of Genetically Encoded Small Molecules, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.
Ronald MicuraDepartment of Organic Chemistry, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.
Dinshaw J PatelStructural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Luciano A MarraffiniLaboratory of Bacteriology, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
Discovery of Antibiotics from Soil Microbiomes Using MetagenomicsR35GM122559 · NIGMS · ROCKEFELLER UNIVERSITY · PI SEAN F BRADY · 2017 to 2026
$4.7M
Tri-Institutional PhD Program in Chemical BiologyT32GM136640 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEREK S TAN · 2020 to 2026
$2.4M
Development of small molecule cGAS inhibitors for repression of dsDNA-triggered interferon expressionR01AI141507 · NIAID · ROCKEFELLER UNIVERSITY · PI TUSCHL, THOMAS · 2019 to 2022
$2.1M
'Class I and III Multi-subunit CRISPR-Cas Surveillance Complexes: Recognition, Cleavage, Autoimmunity and Inhibition’R01GM129430 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PATEL, DINSHAW J · 2019 to 2022
$1.4M
Structure-Activity Based Mechanistic Insights into Cleavage Chemistry by Self-Cleaving Nucleolytic RibozymesR01GM145888 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PATEL, DINSHAW J · 2022 to 2025
$1.3M
NCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI141507NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R01 GM129430NIGMS NIH HHS R01 GM145888NIGMS NIH HHS R35 GM122559NIGMS NIH HHS T32 GM136640
6 · The paper itself

Abstract

The most abundant prokaryotic mechanisms of defense against phage predation involve the recognition and destruction of the infecting DNA. One method of counter-defense is the incorporation of modified nucleobases into the phage genome to avoid interaction with enzymes that target the viral DNA. T-even coliphages replace cytosine with 5-hydroxymethylcytosine (5hmC) that in some cases are further decorated with glucosyl groups. To explore the diversity of immunity genes that recognize 5hmC, we infected a library of metagenomic DNA inserts from uncultured, non-sequenced soil bacteria with a mutant T4 phage that harbored only non-glucosylated 5hmC on its genome. Bacteria that resisted infection carried a DNA glycosylase, Brig3, that specifically excises 5hmC nucleobases to generate abasic sites in the phage genome and prevent viral proliferation. The crystal structure of Brig3 bound to its substrate revealed a catalytic mechanism in which the 5hmC nucleobase is flipped out of the DNA into the active site and replaced by an asparagine residue that inserts into the double helix to contact the complementary guanosine. Brig3 is encoded within an operon that also encodes BapA, a hydrolase that removes glucosyl groups from glucosyl-5hmC present in the genome of otherwise Brig3-resistant T-even phages carrying this hypermodified base. Our results uncover a defense strategy in which the combined action of BapA and Brig3 widens the immune response to restrict the infection of T-even phages with genomes that are either partially or completely glucosylated.

Identifiers

PMID42124595
PMCPMC13160076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.